Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 10/20 | 0.41 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429857 | 0.88 | PRMT6 (0.39) | PRMT6MOKPRMT1CARM1 | |
| SCHEMBL19430238 | 0.87 | PRMT6 (0.39) | PRMT6MOKAOC3 | |
| SCHEMBL19429973 | 0.86 | PRMT6 (0.48) | PRMT6MOKAOC3 | |
| SCHEMBL19430247 | 0.85 | PRMT6 (0.38) | PRMT6MOKPRMT1CARM1HDAC1 | |
| SCHEMBL19430299 | 0.85 | PRMT6 (0.36) | PRMT6MOKPRMT1 | |
| SCHEMBL19430240 | 0.85 | PRMT6 (0.36) | PRMT6MOKPRMT1CARM1HDAC1 | |
| SCHEMBL19430075 | 0.85 | PRMT6 (0.38) | PRMT6MOKPRMT1CARM1KDM5A | |
| SCHEMBL19430236 | 0.84 | PRMT1 (0.40) | PRMT6MOKPRMT1CARM1KDM5A | |
| SCHEMBL19429860 | 0.84 | SMN1; SMN2 (0.44) | PRMT6 | |
| SCHEMBL19430109 | 0.84 | PRMT6 (0.37) | PRMT6MOKPRMT1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT6 4/4885MOK 1964/4885PRMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.